Compugen Reports Third Quarter 2026 Results
MAIA-ovarian fully enrolled; results expected by end of Q1 2027 Phase 3 rilvegostomig high-level results from partner AstraZeneca anticipated in H2 2027 from ARTEMIDE-Biliary01 trial UnigenX™ designed to expand AI-powered discovery engine into tumor-associated antigens for targeted immune...